scorecardresearch
Add as a preferred source on Google
Wednesday, March 11, 2026
TopicSpinal Muscular Atrophy

Topic: Spinal Muscular Atrophy

Roche patent case: Why SC refused to halt Natco’s generic spinal muscular atrophy drug Risdiplam

Roche had approached Delhi High Court, accusing Natco of violating its Indian patent, before going to the Supreme Court with its petition.

India approves Zolgensma, one of world’s costliest drugs. Why it’s sparked hope, but also concern

Zolgensma is the only drug that promises a cure for Spinal Muscular Atrophy, provided it is administered to affected children before the symptoms appear.

New hope for rare disease patients: Rs 900-cr govt project to get high-value drugs at lower rates in works

India has 8.4 to 19 crore rare disease patients, according to health ministry estimates. But current beneficiaries in most cases are kids or those who need relatively less expensive drugs.

On Camera

Modi govt organises Rozgar Melas, but vacant posts show its hiring capacity is limited

Before attempting to answer whether the Rozgar Melas are working, it would be useful to take a look at the performance of the Modi govt on this front since it was formed in May 2014.

Beyond glass ceiling: Redesigning gender rules for India’s economic future

While we celebrate the entry of women into the workforce, we fail to address the structural rigidities that force them out precisely when they are poised for leadership.

India-Bangladesh relations on track—After military intel chief’s visit, envoy goes to Army War College

In a first during his tenure as High Commissioner to India, Riaz Hamidullah addressed JOCAP consisting of tri-forces officers, as New Delhi & Dhaka step up normalisation efforts.

Trump brings the Age of Humiliation for friends. Modi needs stoicism abroad, humility at home

Trump has ushered in the age of humiliation. His method is to push around America’s friends rudely and publicly. He knows none of them can afford to fight back.